Convergence Insufficiency Treatment Trial - Attention and Reading Trial
Convergence Insufficiency Treatment Trial - Attention and Reading Trial
批准号:
9108404
负责人:
MITCHELL M SCHEIMAN
金额:
$60.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2019-04-30
关键词:
AftercareAgeApplications GrantsAttentionAttention deficit hyperactivity disorderBehaviorBinocular VisionBlindnessBlurred visionBudgetsChairpersonChildChild CareChildhoodClinicalClinical TrialsClinical Trials DesignCognitiveControl GroupsControlled Clinical TrialsConvergence InsufficiencyDataData Coordinating CenterDevelopmentDiplopiaEducational CurriculumEvaluationEyeFundingFutureHeadacheHealth PersonnelHome environmentIndividualInstructionInterventionInvestigationLeadLong-Term EffectsManualsMasksMeasuresOralOutcomeOutcome MeasureParentsParticipantPerformancePilot ProjectsPlacebo ControlPlacebosPrincipal InvestigatorProceduresPsychological reinforcementPsychologistRandomizedRandomized Clinical TrialsReadingReportingResearchResolutionS-nitro-N-acetylpenicillamineSpeedSurveysSymptomsTestingVision DisordersWorkachievement testagedbasebehavioral impairmentdevelopmental diseaseevidence basefollow-upimprovedinnovationlistening comprehensionprimary outcomereading abilityreading comprehensionreading difficultiesreduce symptomssecondary outcomesuccesssymptom treatmentsymptomatic improvementteachertreatment effecttreatment grouptreatment trial
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This is the Chairman's grant proposal for the Convergence insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART), a randomized, placebo controlled, clinical trial designed to test the effects of convergence insufficiency (CI) treatment on measures of reading performance and attention. In this trial, 324 children aged 9 to <14 years with symptomatic CI will be randomly assigned to: 1) office- based vergence/accommodative therapy with home-reinforcement or 2) office-based placebo therapy with home reinforcement. After 16 weeks of treatment, examiners masked to treatment group assignment will administer the primary outcome measures for: 1) reading comprehension (Wechsler Individual Achievement test [WIAT-III]) reading comprehension subtest and 2) attention (Strengths & Weaknesses of ADHD Symptoms & Normal Behavior Scale [SWAN]). The Gates MacGinitie-4 test, which uses a format similar to curriculum-based evaluation done in classrooms, will provide a secondary measure of reading comprehension. Other secondary outcome measures include: a test of reading fluency (WIATT III), the SNAP test of attention, the CI Symptom Survey, clinical measures of CI (i.e., near point of convergence and positive fusional vergence at near), and assessments of key reading and cognitive components that impact reading comprehension (pseudo word decoding, word reading, and listening comprehension). Long-term effects on reading achievement and attention will be assessed 1-year post treatment. This Chairman's grant proposal provides the significance, innovation, and approach for the clinical trial including the results of preliminary studies, and the budget for th Study Chairman's office and functions. Accompanying documents include the CITT-ART Manuals of Procedures, and grant proposals from the CITT-ART Data Coordinating Center and 9 participating Clinical Centers. RELEVANCE (See instructions): Symptomatic CI is a common childhood vision disorder frequently associated with symptoms while reading (e.g. loss of place, loss of concentration, frequent re-reading, reading slowly, and trouble remembering what was read). However, the effect of CI treatment on reading and attention is unknown. Results from the proposed study will lead to a better understanding of these relationships and have important implications for educators, psychologists, eye professionals, and other health care providers who care for children with reading and attention problems. The findings will guide hypothesis development for future scientific investigations in children with vision disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Convergence Insufficiency Treatment Trial - Attention and Reading Trial
-
批准号:9204444
-
项目类别:
-
资助金额:$3.55万
-
财政年份:2014
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Convergence Insufficiency Treatment Trial - Attention and Reading Trial
-
批准号:9274971
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2014
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Convergence Insufficiency Treatment Trial - Attention and Reading Trial
-
批准号:8609327
-
项目类别:
-
资助金额:$48.37万
-
财政年份:2014
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:7893441
-
项目类别:
-
资助金额:$6.64万
-
财政年份:2009
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Convergence Insuffiency Treatment Trial
-
批准号:7117229
-
项目类别:
-
资助金额:$44.35万
-
财政年份:2004
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Convergence Insuffiency Treatment Trial
-
批准号:6954166
-
项目类别:
-
资助金额:$67.41万
-
财政年份:2004
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Convergence Insuffiency Treatment Trial
-
批准号:6869737
-
项目类别:
-
资助金额:$64.2万
-
财政年份:2004
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
CONVERGENCE INSUFFICIENCY TREATMENT TRIAL
-
批准号:6191434
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2000
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
COLLABORATIVE OBSERVATIONAL STUDY OF MYOPIA IN COMET CHILDREN
-
批准号:7025712
-
项目类别:
-
资助金额:$18.53万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:7995191
-
项目类别:
-
资助金额:$25.7万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
CORRECTION OF MYOPIA EVALUATION TRIAL (COMET)
-
批准号:2668415
-
项目类别:
-
资助金额:$19.84万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:8204639
-
项目类别:
-
资助金额:$26.1万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
CORRECTION OF MYOPIA EVALUATION TRIAL (COMET)
-
批准号:6164701
-
项目类别:
-
资助金额:$14.3万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:7747992
-
项目类别:
-
资助金额:$25.1万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:7315679
-
项目类别:
-
资助金额:$24.94万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
Collaborative Observational Study of Myopia in Comet Children
-
批准号:8386598
-
项目类别:
-
资助金额:$17.38万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
COLLABORATIVE OBSERVATIONAL STUDY OF MYOPIA IN COMET CHILDREN
-
批准号:6718396
-
项目类别:
-
资助金额:$15.27万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
CORRECTION OF MYOPIA EVALUATION TRIAL (COMET)
-
批准号:6562331
-
项目类别:
-
资助金额:$14.59万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
CORRECTION OF MYOPIA EVALUATION TRIAL (COMET)
-
批准号:2020262
-
项目类别:
-
资助金额:$15.6万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
COLLABORATIVE OBSERVATIONAL STUDY OF MYOPIA IN COMET CHILDREN
-
批准号:6874848
-
项目类别:
-
资助金额:$17.99万
-
财政年份:1997
-
负责人:MITCHELL M SCHEIMAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: